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1 |  RESPONSE TO THE 
COMMENTARY BY BEN- ARI AND 
DELPIRE
We thank Drs. Y. Ben- Ari and E. Delpire1 for their inter-
est in our study2 on the actions of bumetanide, phenobarbital 
(PB), and midazolam on neonatal seizures carried out on a 
novel, physiologically validated model of birth asphyxia3; 
both papers appear in this issue of Epilepsia. In our reply to 
their commentary,1 we wish to rectify the inaccurate descrip-
tions of our model and data. Furthermore, because Ben- Ari 
and Delpire1 suggest that negative data on bumetanide from 
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Abstract
In this response to a commentary by Ben- Ari and Delpire on our recent study on the 
pharmacology of neonatal seizures in a novel, physiologically validated rat model of 
birth asphyxia, we wish to rectify their inaccurate descriptions of our model and data. 
Furthermore, because Ben- Ari and Delpire suggest that negative data on bumetanide 
from preclinical and clinical trials of neonatal seizures have few implications for 
(alleged) bumetanide actions on neurons in other brain disorders, we will discuss this 
topic as well. Based on the poor brain penetration of bumetanide, combined with the 
extremely wide cellular expression patterns of the target protein NKCC1, it is obvi-
ous that the numerous actions of systemically applied bumetanide described in the 
literature are not mediated by the drug's effects on central neurons.
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Key Points
• Seizures are the most common neurological emergency in the neonatal period and 
only poorly respond to antiseizure drugs
• Birth asphyxia is a frequent cause of neonatal seizures, mortality, and poor neu-
rodevelopmental outcome
• Bumetanide was proposed to potentiate the antiseizure activity of phenobarbital, 
but we found that bumetanide is ineffective in a novel rat model of birth asphyxia
• In a commentary article, Drs. Ben- Ari and Delpire discussed our data, but incor-
rectly described our model and the outcome of our experiments
• Here we respond to their commentary and also briefly discuss the (alleged) 
bumetanide actions on neurons in other brain disorders
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preclinical and clinical trials of neonatal seizures have few 
implications for (alleged) bumetanide actions on neurons 
in other brain disorders (see also Ben- Ari et al.4), we will 
discuss this topic as well.
2 |  BIRTH ASPHYXIA IS NOT A 
HYPOXIA- ONLY CONDITION
The original model paper by us3 (see also Pospelov et al.5) is 
focused on showing that exposure to pure hypoxia, as done 
in a large number of studies on rodents, does not mimic birth 
asphyxia (i.e., the combination of hypoxia and hypercapnia), 
and totally fails to reproduce its key physiological and patho-
physiological manifestations within and outside the brain. 
Among the major differences in the physiology and patho-
physiology between pure hypoxia and our asphyxia models 
is that, in the former, seizures are triggered during the insult, 
whereas in our “intermittent asphyxia” protocol (for details 
see Johne et al.2 and Ala- Kurikka et al.3), the seizures com-
mence after the insult, akin to the situation in human neo-
nates. Thus, we were surprised to read in the commentary of 
Ben- Ari and Delpire1 that our work on bumetanide, PB, and 
midazolam (with asphyxia) was done under “experimental 
conditions with very minor differences” when compared to 
the work of Cleary at al.,6 which is based on hypoxia only.
The profound differences between the birth asphyxia and 
hypoxia- only models are likely to account for the finding that 
bumetanide did not potentiate PB's effect on seizures in our 
study,2 whereas such an effect was reported by Cleary et al.6 
Importantly, our negative data on bumetanide are in line with 
those of a clinical trial (the NEMO trial) in human neonates.7
Ben- Ari and Delpire1 argue that “the NEMO trial is irrel-
evant to the use of bumetanide to treat brain disorders,” be-
cause “bumetanide was injected intra- venously at very high 
doses that might indeed be toxic and are certainly not used 
in other clinical situations.” However, this is not true. The 
intravenous doses of bumetanide in the NEMO trial (.05, .1, 
.2, and .3 mg/kg) are in the dose range used (and approved) 
for induction of diuresis in neonates and are generally consid-
ered safe.8 Similar doses were also used in the experiments 
on neonatal seizures in our study2 and the study of Cleary 
et al.6 As correctly noted by Ben- Ari and Delpire,1 we have 
repeatedly shown by direct measurements from brain tissue 
samples that at such low doses of bumetanide, the maximum 
total and unbound brain levels of this drug are at least an 
order of magnitude below concentrations needed to inhibit 
the Na- K- 2Cl cotransporter NKCC1 expressed in central 
neurons.2,9– 11 This is plain fact, and not a result of specu-
lations on pharmacokinetic factors. We will discuss below 
some of the many additional reasons why bumetanide is not 
a promising drug candidate for targeting central nervous sys-
tem (CNS) neurons.
3 |  HYPOXIA, SEIZURES, AND 
INTEGRITY OF THE BLOOD– BRAIN 
BARRIER
Ben- Ari and Delpire1 suggest that “brain levels are, as 
expected, higher after the asphyxia insult” and cite Cleary 
et al.6 in this respect. However, in the hypoxia- only postnatal 
day 10 (P10) rat model used by Cleary et al.,6 bumetanide 
brain levels were not significantly higher than determined by 
the same group in neonatal control rats or, in a previous study, 
in adult rats.12 Thus, 30 minutes following administration of 
.3 mg/kg ip bumetanide, the average brain bumetanide level 
was 1.07 ng/g in P10 rats exposed to hypoxia compared to 
.94 ng/g in controls,6 which is not a relevant (or statistically 
significant) difference. These values have to be corrected by 
the substantial (>80%) binding of bumetanide to lipids and 
proteins in the brain parenchyma.11 Thus, both total and the 
functionally more relevant free bumetanide brain levels are 
far below those needed to inhibit NKCC1.13 Similarly, the 
brain levels of bumetanide determined by us in postasphyxic 
P11 rats with seizures2 were not higher than those determined 
in adult rats,10 further refuting the assumption that brain in-
sults by hypoxia or asphyxia lead to an impairment of blood– 
brain barrier (BBB) integrity, and to a consequent increase in 
the brain penetration of bumetanide in the studies discussed 
presently. It is a widely held misconception that BBB impair-
ment due to brain insults “opens” the BBB to drugs.14
Ben- Ari and Delpire1 note that “the main reason for this 
poor brain availability [of bumetanide] is the fact that ~97% 
of BUM binds to serum proteins, e.g., albumin.” However, 
this is not a major factor in the present context. For instance, 
midazolam is ~95% bound to plasma proteins but, follow-
ing intravenous administration, it has an almost immediate 
onset of anticonvulsant action.15 As shown by Johne et al.2 
for rat neonates, midazolam's brain:plasma concentration 
ratio exceeds 2, which is 400- fold higher compared to the 
brain:plasma ratio of .005 reported at peak brain levels of 
bumetanide in hypoxic rat neonates.6 Rather than plasma pro-
tein binding, the extremely high ionization rate (>99%) of 
bumetanide in plasma and active efflux transport at the BBB 
restrict brain entry of this drug.13,16,17 It is of interest to note 
here that seizures may increase active drug efflux at the BBB 
and thus further reduce drug brain levels.18
4 |  PB AND NEONATAL SEIZURES
In contrast to the comments of Ben- Ari and Delpire,1 we 
certainly do not claim that the convulsive seizures in our 
novel model of birth asphyxia are— to any degree— resistant 
to PB.2 A relatively high (30  mg/kg) dose applied before 
the asphyxia exposure was effective in fully blocking the 
convulsive postasphyxia seizures, whereas nonconvulsant 
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seizures were resistant to PB, which is in line with clinical 
experience.19 The lack of effect of PB when administered 
after the asphyxia simply reflects the brief time window 
(~2– 3 minutes) between the end of the asphyxia and onset 
of seizures in our model, and the slower tissue distribution 
and brain penetration of PB when compared to midazolam, 
as explained in detail in our paper.2 Thus, one of the major 
points of the commentary1 is based on a misunderstanding. 
Although PB is certainly not an ideal treatment for neona-
tal seizures, as stated by Ben- Ari and Delpire,1 it is unfortu-
nately still the best available option in clinical practice20 (but 
see also Davidson et al.21). Notably, midazolam was very ef-
fective in preventing neonatal seizures in our experimental 
study.2 Midazolam is the most effective benzodiazepine cur-
rently available and widely used as an emergency treatment 
for termination of seizures.22 Contrary to the statement by 
Ben- Ari and Delpire,1 midazolam is not related to zolpidem, 
which is a “Z drug” and not a benzodiazepine, but an imida-
zopyridine. Zolpidem differs from midazolam in its effects 
on γ- aminobutyric acid type A (GABAA) receptors and other 
targets.23,24
5 |  DEPOLARIZING GABA 
ACTIONS AND BIRTH ASPHYXIA
We are fully aware that “GABAergic inhibition is particu-
larly activity- dependent and can even reverse polarity.”1 
The widely used term “ionic plasticity” of GABAergic 
signaling was coined by one of us (K.K.; see Rivera 
et al.25; reviewed in Kaila et al.26,27). However, the detailed 
discussion on “depolarizing GABA actions” in the com-
mentary of Ben- Ari and Delpire1 has little to do with our 
work. We do not provide any evidence, nor do we argue 
that NKCC1- dependent depolarizing GABA actions would 
have any role in the postasphyxia seizures in the present 
model. We would also like to note here that we certainly 
do not postulate a “universal common underlying mecha-
nism” (see Summary in Ben- Ari and Delpire1) for neonatal 
encephalopathic seizures.
The NKCC1 expressed in neurons was originally sug-
gested as a promising therapeutic target of bumetanide by 
Dzhala et al.,28 who used kainate (sic) in P9– 10 rats as a 
model of neonatal seizures. In support of their hypothesis 
that neuronal NKCC1 facilitates neonatal seizures in human 
neonates, they erroneously reported that in the neonatal 
human cortex, neuronal expression of NKCC1 would be high 
and KCC2 would be low, leading to depolarizing and excit-
atory GABAergic signaling. Although depolarizing actions 
of GABA on pyramidal neurons have been observed in neo-
natal rats and mice,29 it is important to note that these animals 
are at a much more immature stage of cortical development 
than the human term neonate.30– 32 Work on the expression 
patterns of cation- chloride cotransporters (CCCs) has shown 
that KCC2 mRNA and protein expression are high in human 
cortical neurons at term birth,33– 36 clearly indicating that 
GABAergic transmission is hyperpolarizing at this stage (for 
reviews, see Kaila et al.,26,27.37).
That neonatal seizures and neuronal damage in the pos-
tasphyxic human neocortex might lead to downregulation 
of KCC2 and decreased extrusion of neuronal Cl−— as first 
shown by us in adult kindled adult mice38— is entirely pos-
sible. However, specifically targeting these neurons with 
systemically applied bumetanide is not feasible, as explained 
above.
Moreover, even with direct application of bumetanide or 
any other NKCC1 blocker into the brain, a very high number 
of off- target effects would be expected. This is because neu-
ronal NKCC1 constitutes only a minor fraction of the total 
brain NKCC1, which is expressed in practically all cells in 
the CNS parenchyma, as well as in the BBB and vasculature, 
as described below.
Despite the advances in research on the developmental 
patterns of CCCs in the developing human neocortex (see 
above), the discussion section of a recent clinical study39 on 
the possible mechanisms of bumetanide actions on neonatal 
seizures is still based on the false data and assumptions by 
Dzhala et al.28 In this pilot randomized, controlled double- 
blind clinical trial, neonates with electroencephalograph-
ically (EEG)- confirmed seizures after ≥20 and <40 mg/kg 
PB were randomized to receive additional PB with either 
placebo (control) or .1, .2, or .3 mg/kg bumetanide.39 Drug 
efficacy was not analyzed as percentage seizure reduction, 
which is the benchmark readout in antiseizure medication tri-
als,7,40,41 but as quantitative change in seizure burden. This 
was, strikingly, the case also in the original Dzhala et al. 
study,28 where the conclusions of the “seizure- suppressing 
effect” of bumetanide were based on quantification of EEG 
power (not seizures as such) in six rats treated with kainate 
and six controls. Changes in the spectral power of ictal EEG 
have little relevance to clinical seizure treatment, which aims 
at blocking— not modifying— the electrographic seizure 
activity.42
Similar to the study of Pressler et al.,7 add- on treatment 
with bumetanide was associated with ototoxicity,39 which 
might have been potentiated by the concurrent treatment 
with the aminoglycoside antibiotic gentamicin. As noted by 
Ben- Ari and Delpire,1 ototoxic aminoglycosides should not 
be used together with bumetanide. Notably, however, in both 
clinical studies with bumetanide in neonates,7,39 there was an 
increased risk of ototoxicity also in those neonates that did 
not receive aminoglycosides.
Soul et al.39 concluded that definitive proof of bumeta-
nide's efficacy awaits an appropriately powered Phase 3 trial, 
which we would emphatically advise against because of the 
many reasons explained in this commentary.
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6 |  CELLULAR TARGETS OF 
BUMETANIDE OUTSIDE THE BRAIN
It is obvious that the data presented by Soul et al.39 (or any 
data from clinical trials using bumetanide) are not proof of 
concept that bumetanide acts by inhibiting NKCC1 in neu-
rons or any other brain cells. Here, we would like to call at-
tention to the finding that NKCC1 is expressed in practically 
all cells and organ systems in the body. Therefore, nonspe-
cific manipulation of NKCC1 in the organism can lead to 
unexpected effects, and especially so if research is based on 
the outdated dogma referred to above. For instance, we found 
very recently that constitutive disruption of expression of the 
Slc12a2 gene, which codes for NKCC1, leads to enhanced 
severity of seizures in the widely used kainate model of tem-
poral lobe epilepsy.43
Interestingly, systemic administration of bumetanide has 
an anti- inflammatory action outside the brain, whereas di-
rect application into the brain in vivo has the opposite ef-
fect.44 There are also intriguing findings obtained using low 
systemic doses of bumetanide and other diuretics in rodents 
(e.g., Krystal et al.,45 and Marguet et al.46) that point to ben-
eficial actions, based on unidentified mechanisms outside 
the brain. However, effects of bumetanide may also be me-
diated by targets other than NKCC1. A recent example is the 
brain- permeant bumetanide derivative, bumepamine, which 
despite its structural similarity to bumetanide does not in-
hibit NKCC1 at all, but is a potent diuretic.11,47,48 Strikingly, 
bumepamine is much more effective than bumetanide at 
potentiating the effect of PB on neonatal seizures in our 
birth- asphyxia seizure model,49 but again, the underlying 
mechanisms remain to be identified.
7 |  CONCLUSIONS
Although CCCs, such as NKCC1, are considered attractive 
CNS drug targets, bumetanide and other existing NKCC1 
inhibitors are suboptimal because of pharmacokinetic con-
straints and lack of target specificity at the cellular level. 
Furthermore, with respect to the presumed role of neuronal 
NKCC1 in diverse neurological and psychiatric disorders, a 
major caveat here is that our understanding of the spatiotem-
poral expression patterns of NKCC1 in the brain is still in 
its infancy.50 NKCC1 expression in certain glial subtypes is 
much higher than in neurons,50 and glial NKCC1 seems to 
regulate neuronal signaling and plasticity in a robust man-
ner (e,g., long- term potentiation51). We do not argue that 
bumetanide may not be beneficial in some brain disorders, 
such as autism spectrum disorders,1,4 but such effects of bu-
metanide are obviously not related to inhibition of NKCC1 
in CNS neurons. Effects of bumetanide on NKCC1 located 
in the BBB or in the hypothalamic– pituitary– adrenal axis, as 
well as secondary actions resulting from bumetanide's strong 
diuretic activity, may all be relevant here (see Puskarjov 
et al.13). Putative targets also include the choroid plexus, 
which has a uniquely high level of NKCC1.50 This epithe-
lium is directly exposed to blood- borne drugs and has been 
shown to regulate the neuronal microenvironment of imma-
ture cortical neurons during brain development.52 Finally, 
chronic diuresis of offspring might influence parental atten-
tion and behavior in both mice and men, for the benefit of 
social and other aspects of brain development. We are con-
vinced that open- minded research on the diverse effects of 
bumetanide will enhance our understanding of the multiple 
roles of NKCC1 in cells and organ systems, thus paving the 
way to rational design of NKCC1- modulatory drugs and to 
possible therapeutic applications thereof.
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